Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Radiofrequency Ablation to Treat Loco-Regional Recurrence of Well-Differentiated Thyroid Carcinoma

  • Lee, Sun Jin (Department of Radiology, Chung-Ang University Hospital) ;
  • Jung, So Lyung (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Bum Soo (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Ahn, Kook Jin (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Choi, Hyun Seok (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Lim, Dong Jun (Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Min Hee (Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Bae, Ja Seong (Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Min Sik (Department of Otolaryngology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Jung, Chan Kwon (Department of Clinical Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Chong, Se Min (Department of Radiology, Chung-Ang University Hospital)
  • Received : 2013.10.16
  • Accepted : 2014.08.12
  • Published : 2014.12.01
⟨ Previous Next ⟩

Abstract

Objective: To evaluate the efficacy of radiofrequency ablation (RFA) in the treatment of loco-regional, recurrent, and well-differentiated thyroid carcinoma. Materials and Methods: Thirty-five recurrent well-differentiated thyroid carcinomas (RTC) in 32 patients were treated with RFA, between March 2008 and October 2011. RTCs were detected by regular follow-up ultrasound and confirmed by biopsy. All patients had fewer than 3 RTCs in the neck and were at high surgical risk or refused to undergo repeated surgery. Average number of RFA sessions were 1.3 (range 1-3). Post-RFA biopsy and ultrasound were performed. The mean follow-up period was 30 months. Pre- and post-RFA serum thyroglobulin values were evaluated. Results: Thirty-one patients with 33 RTCs were treated with RFA only, whereas 1 patient with 2 RTCs was treated with RFA followed by surgery. At the last follow-up ultrasound, 31 (94%) of the 33 RTCs treated with RFA alone completely disappeared and the remaining 2 (6%) RTCs showed decreased volume. The largest diameter and volume of the 33 RTCs were markedly decreased by 93.2% (from $8.1{\pm}3.4$ mm to $0.6{\pm}1.8$ mm, p < 0.001) and 96.4% (from $173.9{\pm}198.7mm^3$ to $6.2{\pm}27.9mm^3$, p < 0.001), respectively. Twenty of the 21 RTCs evaluated with post-RFA biopsies (95%) were negative for malignancy. One (5%) showed remaining tumor that was removed surgically. The serum thyroglobulin was decreased in 19 of 26 patients (73%). Voice change developed immediately after RFA in 6 patients (19%) and was spontaneously recovered in 5 patients (83%). Conclusion: Radiofrequency ablation can be effective in treating loco-regional, recurrent, and well-differentiated thyroid carcinoma in patients at high surgical risk.

Keywords

References

  1. Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease, 9th ed. Philadelphia: Saunders, 2014:1073-1139
  2. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997;79:564-573 https://doi.org/10.1002/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0
  3. Dupuy DE, Monchik JM. Radiofrequency ablation of recurrent thyroid cancer. In: Ellis LM, Curley SA, Tanabe KK, eds. Radiofrequency Ablation for Cancer: Current indications, techniques, and outcomes. New York: Springer-Verlag, 2003:213-223
  4. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997;82:3553-3562 https://doi.org/10.1210/jcem.82.11.4373
  5. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992;75:714-720
  6. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981;70:511-518 https://doi.org/10.1016/0002-9343(81)90573-8
  7. Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB. Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery 2001;130:921-930 https://doi.org/10.1067/msy.2001.118370
  8. Dupuy DE, Monchik JM, Decrea C, Pisharodi L. Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery 2001;130:971-977 https://doi.org/10.1067/msy.2001.118708
  9. Monchik JM, Donatini G, Iannuccilli J, Dupuy DE. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg 2006;244:296-304 https://doi.org/10.1097/01.sla.0000217685.85467.2d
  10. Baek JH, Kim YS, Sung JY, Choi H, Lee JH. Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation. AJR Am J Roentgenol 2011;197:W331-W336 https://doi.org/10.2214/AJR.10.5345
  11. Shin JE, Baek JH, Lee JH. Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges. Curr Opin Oncol 2013;25:14-19 https://doi.org/10.1097/CCO.0b013e32835a583d
  12. Park KW, Shin JH, Han BK, Ko EY, Chung JH. Inoperable symptomatic recurrent thyroid cancers: preliminary result of radiofrequency ablation. Ann Surg Oncol 2011;18:2564-2568 https://doi.org/10.1245/s10434-011-1619-1
  13. Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol 2002;178:699-704 https://doi.org/10.2214/ajr.178.3.1780699
  14. Na DG, Lee JH, Jung SL, Kim JH, Sung JY, Shin JH, et al. Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations. Korean J Radiol 2012;13:117-125 https://doi.org/10.3348/kjr.2012.13.2.117
  15. Baek JH, Lee JH, Sung JY, Bae JI, Kim KT, Sim J, et al. Complications encountered in the treatment of benign thyroid nodules with US-guided radiofrequency ablation: a multicenter study. Radiology 2012;262:335-342 https://doi.org/10.1148/radiol.11110416
  16. Goldberg SN, Charboneau JW, Dodd GD 3rd, Dupuy DE, Gervais DA, Gillams AR, et al. Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology 2003;228:335-345 https://doi.org/10.1148/radiol.2282021787
  17. Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 2003;14(9 Pt 2):S199-S202 https://doi.org/10.1097/01.RVI.0000094584.83406.3e
  18. Papini E, Bizzarri G, Bianchini A, Valle D, Misischi I, Guglielmi R, et al. Percutaneous ultrasound-guided laser ablation is effective for treating selected nodal metastases in papillary thyroid cancer. J Clin Endocrinol Metab 2013;98:E92-E97 https://doi.org/10.1210/jc.2012-2991
  19. Mauri G, Cova L, Tondolo T, Ierace T, Baroli A, Di Mauro E, et al. Percutaneous laser ablation of metastatic lymph nodes in the neck from papillary thyroid carcinoma: preliminary results. J Clin Endocrinol Metab 2013;98:E1203-E1207 https://doi.org/10.1210/jc.2013-1140
  20. Pacella CM, Bizzarri G, Guglielmi R, Anelli V, Bianchini A, Crescenzi A, et al. Thyroid tissue: US-guided percutaneous interstitial laser ablation-a feasibility study. Radiology 2000;217:673-677 https://doi.org/10.1148/radiology.217.3.r00dc09673

Cited by

  1. Surgical and Pathological Changes after Radiofrequency Ablation of Thyroid Nodules vol.2015, pp.None, 2014, https://doi.org/10.1155/2015/576576
  2. Radiofrequency versus Ethanol Ablation for Treating Predominantly Cystic Thyroid Nodules: A Randomized Clinical Trial vol.16, pp.6, 2015, https://doi.org/10.3348/kjr.2015.16.6.1332
  3. Meta-analysis of radiofrequency ablation for treating the local recurrence of thyroid cancers vol.39, pp.8, 2016, https://doi.org/10.1007/s40618-016-0450-8
  4. Efficacy and Safety of Radiofrequency and Ethanol Ablation for Treating Locally Recurrent Thyroid Cancer: A Systematic Review and Meta-Analysis vol.26, pp.3, 2014, https://doi.org/10.1089/thy.2015.0545
  5. Papillary Thyroid Carcinoma Treated with Radiofrequency Ablation in a Patient with Hypertrophic Cardiomyopathy: A Case Report vol.17, pp.4, 2016, https://doi.org/10.3348/kjr.2016.17.4.558
  6. External‐beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society vol.38, pp.4, 2016, https://doi.org/10.1002/hed.24357
  7. Radiofrequency ablation of benign thyroid nodules: evaluation of the treatment efficacy using ultrasonography vol.35, pp.3, 2014, https://doi.org/10.14366/usg.15083
  8. Radiofrequency ablation of low-risk small papillary thyroidcarcinoma: preliminary results for patients ineligible for surgery vol.33, pp.2, 2014, https://doi.org/10.1080/02656736.2016.1230893
  9. Thyroid Radiofrequency Ablation: Updates on Innovative Devices and Techniques vol.18, pp.4, 2014, https://doi.org/10.3348/kjr.2017.18.4.615
  10. 2017 Thyroid Radiofrequency Ablation Guideline: Korean Society of Thyroid Radiology vol.19, pp.4, 2018, https://doi.org/10.3348/kjr.2018.19.4.632
  11. Efficacy and Affecting Factors of 131 I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma vol.8, pp.None, 2014, https://doi.org/10.3389/fonc.2018.00640
  12. Radiofrequency ablation for treatment of locally recurrent thyroid cancer presenting as a metastatic lymph node with dense macrocalcification: A case report and literature review vol.97, pp.9, 2014, https://doi.org/10.1097/md.0000000000010003
  13. mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study vol.41, pp.12, 2018, https://doi.org/10.1007/s40618-018-0886-0
  14. Management strategy for nerve damage during radiofrequency ablation of thyroid nodules vol.36, pp.1, 2014, https://doi.org/10.1080/02656736.2018.1554826
  15. Comparison of efficacy and complications between radiofrequency ablation and repeat surgery in the treatment of locally recurrent thyroid cancers: a single-center propensity score matching study vol.36, pp.1, 2014, https://doi.org/10.1080/02656736.2019.1571248
  16. Percutaneous ultrasound-guided laser ablation for the treatment of cervical tuberculous lymphadenitis: a pilot study vol.47, pp.4, 2019, https://doi.org/10.1177/0300060518821818
  17. Ethanol ablation as a treatment strategy for benign cystic thyroid nodules: a comparison of the ethanol retention and aspiration techniques vol.38, pp.2, 2014, https://doi.org/10.14366/usg.18033
  18. Summary of the 2017 thyroid radiofrequency ablation guideline and comparison with the 2012 guideline vol.38, pp.2, 2014, https://doi.org/10.14366/usg.18044
  19. Ethanol Ablation of the Thyroid Nodules: 2018 Consensus Statement by the Korean Society of Thyroid Radiology vol.20, pp.4, 2019, https://doi.org/10.3348/kjr.2018.0696
  20. Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer vol.29, pp.9, 2019, https://doi.org/10.1007/s00330-019-06063-5
  21. The Clinical Application of Core-Needle Biopsy after Radiofrequency Ablation for Low-risk Papillary Thyroid Microcarcinoma: A Large Cohort of 202 Patients Study vol.11, pp.18, 2014, https://doi.org/10.7150/jca.42673
  22. Ultrasound-Guided Percutaneous Ethanol Ablation for the Management of Recurrent Thyroid Cancer: Evaluation of Efficacy and Impact on Disease Course vol.13, pp.2, 2014, https://doi.org/10.11106/ijt.2020.13.2.128
  23. Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities vol.22, pp.6, 2021, https://doi.org/10.3390/ijms22063117
  24. Treatment Efficacy of Radiofrequency Ablation for Recurrent Tumor at the Central Compartment After Hemithyroidectomy vol.216, pp.6, 2014, https://doi.org/10.2214/ajr.20.23434
  25. Ultrasound-Guided Radiofrequency Ablation Versus Thyroid Lobectomy for Low-Risk Papillary Thyroid Microcarcinoma: A Propensity-Matched Cohort Study of 884 Patients vol.31, pp.11, 2014, https://doi.org/10.1089/thy.2021.0100
  26. Radiofrequency ablation and thyroid cancer: review of the current literature vol.43, pp.1, 2014, https://doi.org/10.1016/j.amjoto.2021.103204